Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Microbix Biosystems granted U.S. patent for its influenza vaccine yield enhancement technology

24 Oct 2007 - Microbix Biosystems Inc. has been granted a patent by the U.S. Patent Office for its technology - VIRUSMAX(TM) - which enables vaccine manufacturers to double the amount of influenza vaccine they produce each year.
 
According to the company, Microbix' discovery has enormous implications for protecting more people during a pandemic. Patents are also being allowed in Canada, India and Australia, and a number of other applications in major markets are currently pending.
 
"We're delighted that we now have strong patent protection as we engage in assisting manufacturers increase production" said William J. Gastle, CEO of Microbix. The company's technology will be licensed to manufacturers on a non-exclusive basis.
 
VIRUSMAX(TM) can be implemented quickly and cost-effectively by manufactures, allowing them to ramp up production in a matter of months. Microbix has established a Special Workgroup for Applied Technology Transfer (SWATT) to help manufacturers adopt the process. The SWATT team is now being sent to various facilities to assist customers in implementing the technology and training local personnel.